3,7,8,2'-Tetrahydroxyflavone
3,7-Dihydroxyflavone
4'-Dimethylamino-7,8-dihydroxyflavone
7,3′-Dihydroxyflavone
7,8,2'-Trihydroxyflavone
7,8,3'-Trihydroxyflavone
7,8-Dihydroxyflavone
ABT-110
ALE-0540
AM7 (drug)
AMG-458
ANA-12
ANXA2
ASP-6294
ATC code L01
AVE-1642
AXL receptor tyrosine kinase
AZD-6918
Abemaciclib
Acalabrutinib
Adagrasib
Adipotide
Adrenocortical carcinoma
Adrenomedullin
Afatinib
Aflibercept
Agerafenib
Alacizumab pegol
Albumin
Alectinib
Alemtuzumab
Alpelisib
Altiratinib
American Society of Health-System Pharmacists
Amitriptyline
Amivantamab
Amphiregulin
Amuvatinib
Anaplastic astrocytoma
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Ancestim
Angiopoietin 1
Angiopoietin 2
Angiopoietin 3
Angiopoietin 4
Angiopoietin receptor
Anti-cancer medication
Antineoplastic
Aprutumab
Aprutumab ixadotin
Artemin
Asciminib
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
Axokine
BMS-754807
BMS-777607
BNN-20
BNN-27
BRAF (gene)
Baricitinib
Bcr-abl fusion protein
Becaplermin
Belantamab mafodotin
Bermekimab
Betacellulin
Bevacizumab
Bilirubin
Binimetinib
Biological half-life
Black box warning
Bladder cancer
Blinatumomab
Bosutinib
Brain-derived neurotrophic factor
Brain tumor
Breast cancer
Brentuximab vedotin
Brigatinib
Bruton's tyrosine kinase
Burosumab
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
CE-245677
CH-7057288
CSPG5
CYP3A4
Cabozantinib (data page)
Cancer immunotherapy
Canertinib
Capmatinib
Catumaxomab
Cediranib
Cemiplimab
Cenegermin
Cerebrolysin
Ceritinib
Cervical cancer
Cetuximab
ChEBI
ChEMBL
ChemSpider
Chemical formula
Chemotherapy-induced acral erythema
Ciliary neurotrophic factor receptor
Cirrhosis
Cixutumumab
ClinicalTrials.gov
Cobimetinib
Colony-stimulating factor
Colorectal cancer
CompTox Chemicals Dashboard
Connective tissue growth factor
Copanlisib
Cosibelimab
Crenolanib
Crizotinib
Cyclotraxin B
DMAQ-B1
DS-6051
Dabrafenib
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Dapiclermin
Daratumumab
Dasatinib
Dehydroepiandrosterone
Dehydroepiandrosterone sulfate
Denileukin diftitox
Deoxygedunin
Depatuxizumab
Depatuxizumab mafodotin
Deprenyl
Des(1-3)IGF-1
Dexamethasone
Dihexa
Dinutuximab beta
Diosmetin
Doi (identifier)
Dostarlimab
DrugBank
Drug metabolism
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
ECHA InfoCard
EFNA1
EFNA2
EFNA3
EFNA4
EFNA5
EFNB1
EFNB2
EFNB3
EML4
EVT-901
Edrecolomab
Elevated transaminases
Elotuzumab
Elranatamab
Emibetuzumab
Encorafenib
Endometrial cancer
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Ephrin
Epidermal growth factor
Epidermal growth factor receptor
Epigen
Epiregulin
ErbB
Erdafitinib
Erlotinib
Ersofermin
Ertumaxomab
Erythropoietin
Esophageal cancer
European Medicines Agency
Everolimus
Evinacumab
Excretion
Exelixis
Exotoxin
FGF1
FGF10
FGF15/19
FGF17
FGF18
FGF19
FGF2
FGF20
FGF22
FGF23
FGF3
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FX007
Fasinumab
Feces
Fedratinib
Fibroblast growth factor
Fibroblast growth factor receptor
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor 4
Ficlatuzumab
Figitumumab
Filgotinib
Fistulas
Flanvotumab
Fms-like tyrosine kinase 3
Food and Drug Administration
Foretinib
Fosgonimeton
Frunevetmab
Fruquintinib
Fulranumab
Fusion protein
Futibatinib
Futuximab
GBR-900
GFRα1
GFRα2
GFRα3
GFRα4
GZ-389988
Gambogic amide
Ganitumab
Gastrointestinal perforation
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glia maturation factor
Glial cell line-derived neurotrophic factor
Glioblastoma
Glofitamab
Glucose-6-phosphate isomerase
Glypromate
Golvatinib
Gossypetin
Grandinin
Growth factor receptor
HER2/neu
HER3
HER4
HIOC
Head and neck cancer
Health Canada
Hedgehog signaling pathway
Heparin-binding EGF-like growth factor
Hepatocellular carcinoma
Hepatocyte growth factor
Hepatocyte growth factor receptor
Hepatoma-derived growth factor
Hypertensive crisis
IGF-1 LR3
IGFBP1
IGFBP2
IGFBP3
IGFBP4
IGFBP5
IGFBP6
IGFBP7
INCB28060
IUPAC nomenclature of chemistry
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Inavolisib
Infigratinib
Inotuzumab ozogamicin
Insulin
Insulin-like growth factor-binding protein
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Insulin-like growth factor 2
Insulin-like growth factor 2 receptor
Interleukin
Interleukin 2
International Chemical Identifier
Ipilimumab
Ipsen
Isatuximab
JNJ-38877605
JSmol
Janus kinase
K252a
KEGG
KRAS
Keratinocyte growth factor
Kidney cancer
LEVI-04
LM22A-4
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Leukemia inhibitory factor
Liatermin
Linsitinib
Liver
Loncastuximab tesirine
Lorlatinib
Low-affinity nerve growth factor receptor
Lymphatic system
Lymphoma
MEDI-578
MEN1
MK-2461
MTOR inhibitor
Macrophage-stimulating protein
Masitinib
Matuzumab
Mecasermin
Mecasermin rinfabate
MedlinePlus
Medullary thyroid cancer
Melanoma
Merkel-cell carcinoma
Midkine
Midostaurin
Migration-stimulating factor
Milciclib
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody therapy
Mosunetuzumab
Motesanib
Moxetumomab pasudotox
Mubritinib
Multidrug resistance-associated protein 2
Murodermin
Myeloid
N-Acetylserotonin
NRG2
NRG3
NRG4
NVP-ADW742
NVP-AEW541
Naxitamab
Necitumumab
Nepidermin
Neratinib
Nerve growth factor
Nesvacumab
Neuregulin
Neuregulin-1
Neuroendocrine tumor
Neurofibromatosis type I
Neurotrophin-3
Neurotrophin-4
Neurturin
New drug application
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Non-small-cell lung carcinoma
Norwogonin
ONO-4474
ONO-5390556
OSl-906
Obinutuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Onartuzumab
Oncomodulin
Oportuzumab monatox
Oral administration
Orelabrutinib
Orphan drug
Osimertinib
PDGFA
PDGFB
PDGFC
PDGFD
PF-04217903
PF-2341066
PHA-665752
PLX-7486
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Palifermin
Panitumumab
Parsaclisib
Patritumab
Pazopanib
Pegaptanib
Pembrolizumab
Pemigatinib
Persephin
Pertuzumab
Pexidartinib
Pharmacokinetics
Pi3K inhibitor
Pirtobrutinib
Pituitary adenylate cyclase-activating peptide
Placental growth factor
Plasma protein binding
Platelet-derived growth factor
Platelet-derived growth factor receptor
Pleiotrophin
Polatuzumab vedotin
Ponatinib
Posterior reversible encephalopathy syndrome
Pralsetinib
Pregnancy category
Prescription drug
Proapoptotic
Prohibitin
Prolgolimab
Prostate cancer
PubChem
Public domain
Quizartinib
R13 (drug)
R1507
R7 (drug)
RBM-004
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Ranevetmab
Ranibizumab
ReN-1820
Rebastinib
Receptor modulator
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Renal cell carcinoma
Renalase
Repifermin
Repotrectinib
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Rituximab
Robatumumab
Rociletinib
Route of administration
Ruxolitinib
S2CID (identifier)
SNA-120
SU-11274
Sabatolimab
Sacituzumab govitecan
Sarcoma
Selpercatinib
Selumetinib
Semaxanib
Seribantumab
Serplulimab
Simplified molecular-input line-entry system